Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07527143 · ClinicalTrials.gov registry record
Acceptability of Testing DNA Markers in Vaginal Fluid for the Detection of Endometrial Cancer
A clinical trial, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 25
- Enrollment target
NCT07527143: Recruiting study, sponsored by Mayo Clinic.
NCT07527143 is a clinical trial that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07527143 is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 25 participants
- Enrollment target
Study Summary
This study evaluates how women feel about using DNA from a vaginal fluid collection for early detection of endometrial cancer.
Primary Outcome
Information collected during a 30-minute virtual interview using mostly open-ended questions. The interviews will be transcribed and reviewed by the study team to identity themes and create coding categories. Coding categories will be used to organize the data into subthemes. Results will be reported in aggregate. Aggregate results will be disseminated to participants if they elect to receive them.
Interventions
- OTHER Non-Interventional Study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2026-06-10 |
| Est. Completion | 2027-06-10 |
What NCT07527143 shows while recruiting
NCT07527143 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 25 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Non-Interventional Study is the first listed.
NCT07527143 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07527143 about?
NCT07527143 is a clinical study titled "Acceptability of Testing DNA Markers in Vaginal Fluid for the Detection of Endometrial Cancer". This study evaluates how women feel about using DNA from a vaginal fluid collection for early detection of endometrial cancer.
What is the current status of trial NCT07527143?
This trial is currently recruiting. The enrollment target is 25 participants. The study started on 2026-06-10. Estimated completion is 2027-06-10.
What interventions are being tested in trial NCT07527143?
The interventions under investigation include: Non-Interventional Study (OTHER).
Who is sponsoring clinical trial NCT07527143?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI